Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
AstraZeneca Pharma India Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
AstraZeneca Pharma India has a total shareholder equity of ₹7.1B and total debt of ₹45.9M, which brings its debt-to-equity ratio to 0.6%. Its total assets and total liabilities are ₹10.8B and ₹3.7B respectively. AstraZeneca Pharma India's EBIT is ₹1.4B making its interest coverage ratio -4.5. It has cash and short-term investments of ₹5.1B.
Anahtar bilgiler
0.6%
Borç/özkaynak oranı
₹45.90m
Borç
| Faiz karşılama oranı | -4.5x |
| Nakit | ₹5.06b |
| Eşitlik | ₹7.12b |
| Toplam yükümlülükler | ₹3.66b |
| Toplam varlıklar | ₹10.78b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 506820's short term assets (₹9.3B) exceed its short term liabilities (₹3.6B).
Uzun Vadeli Yükümlülükler: 506820's short term assets (₹9.3B) exceed its long term liabilities (₹89.9M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 506820 has more cash than its total debt.
Borcun Azaltılması: 506820's debt to equity ratio has increased from 0% to 0.6% over the past 5 years.
Borç Kapsamı: 506820's debt is well covered by operating cash flow (607.2%).
Faiz Kapsamı: 506820 earns more interest than it pays, so coverage of interest payments is not a concern.